Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 2:35 PM ET


Company Overview of Transcept Pharmaceuticals, Inc.

Company Overview

As of October 30, 2014, Transcept Pharmaceuticals, Inc. was acquired by Paratek Pharmaceuticals, Inc., in a reverse merger transaction. Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. The company principal product include Intermezzo sublingual tablet C-IV, a sublingual formulation of zolpidem for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Its lead product candidate is TO-2070, a rapidly absorbed treatment for acute migraine. The company has a collaboration agreement with Pur...

1003 West Cutting Boulevard

Suite 110

Point Richmond, CA 94804

United States

Founded in 2002

8 Employees



Key Executives for Transcept Pharmaceuticals, Inc.

Transcept Pharmaceuticals, Inc. does not have any Key Executives recorded.

Transcept Pharmaceuticals, Inc. Key Developments

Transcept Pharmaceuticals, Inc.(NasdaqGM:TSPT) dropped from NASDAQ Composite Index

Transcept Pharmaceuticals, Inc. will be removed from the NASDAQ Composite Index.

Transcept Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Oct 28, 2014

Transcept Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Oct 28, 2014.

Transcept Pharmaceuticals Declares Special Dividend, Payable on October 29, 2014

Transcept Pharmaceuticals declared a special dividend, in connection with its merger with Paratek Pharmaceuticals, in the initial cash amount of $0.6674 per share on Transcept's common stock and the right to receive certain contingent cash amounts, in the future, on a pro rata basis. All payments will be made to stockholders of record at the close of business on October 24, 2014. The initial cash payment will be made on October 29, 2014.

Similar Private Companies By Industry

Company Name Region
X-Gen Pharmaceuticals, Inc. United States
The Tapemark Company United States
Salix Pharmaceuticals, Inc. United States
Union Springs Pharmaceuticals, LLC United States
Sebela Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Transcept Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at